On 15 November 2023, the U.S. Food and Drug Administration gave its approval to capivasertib, marketed under the name Truqap, for a defined subset of breast‑cancer patients. The drug is indicated for individuals whose tumours are hormone‑receptor‑positive (HR+) and lack HER2 protein expression (HER2‑negative).
It is not a stand‑alone therapy; the approval specifies use in combination with fulvestrant, an established estrogen‑blocking agent. The HR+, HER2‑negative category represents roughly 70 % of all breast‑cancer diagnoses. Tumour cells in this group carry receptors for estrogen or progesterone but do not over‑express HER2, a distinction that determines eligibility for the new regimen.
Capivasertib is taken orally as a pill, offering an alternative to the infusion‑based treatments that many patients find burdensome. Regulators described capivasertib as a “first‑in‑class” medication, meaning its mechanism differs from existing therapies.
It targets the PI3K/AKT signalling pathway by inhibiting the AKT protein, a key driver of cancer‑cell growth. By disrupting this pathway, the drug aims to halt the proliferative signals that allow tumours to progress despite prior endocrine therapy. Clinical data that supported the approval showed that the capivasertib‑fulvestrant combination could produce tumour shrinkage or disease stability in patients whose disease had advanced after standard hormone‑blocking treatments.
While the FDA did not label the drug a cure, the agency concluded that the therapeutic benefits outweighed the identified risks. Adverse‑event information accompanies the approval.
The most frequently reported side effect is diarrhoea, followed by skin‑related reactions. Laboratory changes include elevated blood glucose, reductions in lymphocyte counts and hemoglobin levels. Additional reported effects are nausea, fatigue, vomiting and stomatitis. Because of these risks, physicians will need to conduct regular blood‑work monitoring and provide supportive care for gastrointestinal and dermatologic symptoms.
The timing of the approval is notable. Over the past decade, research and new‑drug introductions have accelerated for triple‑negative and HER2‑positive breast cancers, while the HR+, HER2‑negative subtype has lagged behind.
Capivasertib therefore narrows that development gap, adding a novel oral option for patients with advanced or metastatic disease who have exhausted standard endocrine options. Pricing details for Truqap have not yet been disclosed by the developer, and the cost will likely influence patient access. As with many recent oncology agents, the price could be substantial, making insurance coverage and patient‑assistance programs critical for uptake.
In summary, the FDA’s clearance of capivasertib marks the introduction of a new class of targeted oral therapy for a prevalent form of breast cancer. When paired with fulvestrant, the regimen offers oncologists a dual approach—blocking hormonal signaling while simultaneously cutting off a growth‑promoting pathway.
For patients who have seen limited success with existing treatments, the availability of Truqap provides an additional therapeutic avenue, albeit one that requires careful management of side effects and close clinical monitoring.
